铁和认知障碍:解开联系和潜在的治疗点
Soudabeh Naderi1, Fariba Khodagholi1, Mahyar Janahmadi2
1Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Neuropharmacology
|November 9, 2024
概括
铁亡,一种涉及铁和氧化应激的细胞死亡途径,可能是导致神经退行性疾病认知障碍的常见机制. 向铁亡提供了一个有前途的新治疗策略,用于阿尔茨海默氏症和帕金森症等疾病.
科学领域:
- 神经生物学 神经生物学 神经生物学
- 细胞生物学 细胞生物学
- 神经退行性疾病 神经退行性疾病
背景情况:
- 神经退行性疾病,如阿尔茨海默氏症和帕金森病共享认知障碍和细胞死亡.
- 现有的治疗方法有限,这促使人们对新的细胞死亡机制进行研究.
研究的目的:
- 为了探索铁灭症在与神经退行相关的认知障碍中的作用.
- 审查证据,将铁亡生物标志物与认知衰退联系起来.
- 讨论针对铁亡的治疗策略.
主要方法:
- 关于铁亡机制和生物标志物的文献综述.
- 对将铁亡与神经退行和认知障碍联系起来的研究进行分析.
- 评估潜在的治疗药物,以铁死为向.
主要成果:
- 铁,以铁失衡和脂质过氧化为特征,与神经退行有关.
- 铁亡的生物标志物与受影响个体的认知障碍相关.
- 抗氧化剂和铁合剂显示出抑制铁的潜力.
结论:
- 铁亡是神经退行性认知障碍中潜在的常见途径.
- 通过抗氧化剂和铁化剂等药物向铁化,提供了一个新的治疗途径.
- 对铁灭的机制和治疗干预的进一步研究是有必要的.
相关概念视频
Necrosis
4.3K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.3K
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K


